A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors

Trial Profile

A Phase 1, Dose Escalation Study Of PF-06263507 In Patients With Advanced Solid Tumors

Discontinued
Phase of Trial: Phase I

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs PF 6263507 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 09 Jan 2017 Results assessing safety, pharmacokinetics, and preliminary antitumor activity of PF-06263507 in patients with advanced solid tumors published in the Investigational New Drugs.
    • 17 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top